BioAtla
BCAB
53 hedge funds and large institutions have $530M invested in BioAtla in 2020 Q4 according to their latest regulatory filings, with 53 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.97% more ownership
Funds ownership: 0% → 0.97% (+0.97%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$106M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$76.6M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$65.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$59.5M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$44M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of America
Charlotte,
North Carolina
| $6K | +$5.01K | +3 | New |
|
52
Citigroup
New York
| $6K | +$6.69K | +4 | New |
|
53
Osaic Holdings
Scottsdale,
Arizona
| $2K | +$1.67K | +1 | New |
|
BCAB Hedge Fund Activity: Q4 2020 in Review
53 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in BioAtla (BCAB) for Q4 2020, worth a combined $530M.
Buyers outnumbered sellers: 53 funds opened new BCAB positions and 0 closed out — a net gain of 53 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $106M.
- 53 institutional investors held BioAtla (BCAB) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $530M of BioAtla stock for Q4 2020.
- 53 funds opened new BioAtla positions in Q4 2020 and 0 closed out, a net change of +53 holders.
- The largest BioAtla buyer in Q4 2020 was Soleus Capital Management, an estimated $106M added.
Based on aggregated 13F filings for Q4 2020.